Newsletter 5: PCOS and Insulin Resistance: What Studies Show, Proven Treatments, and Lifestyle Wins
For women navigating prediabetes – the metabolic overlap you need to know.
Hi Reader,
You've likely heard PCOS called a "hormone disorder." But for our prediabetes community - especially women - it's far more: a metabolic powerhouse where insulin resistance (IR) drives 70% of cases, amplifying your prediabetes risk 3-5x.
Stuck cycles of high insulin fuel excess androgens, ovarian chaos, and stubborn belly fat. The good news? Targeted action reverses this - not just symptoms, but the root.
Today, we unpack what studies actually show, effective treatments, and best lifestyle shifts for insulin sensitivity. Evidence from 2025-2026 trials guides every point.
Let's reclaim metabolic control.
What Studies Actually Show: IR as PCOS's Core Engine
Insulin resistance isn't a side effect - it's foundational. Up to 70% of PCOS patients have IR, even lean ones. Hyperinsulinemia overstimulates ovarian theca cells, spiking androgens like testosterone by 2-3x and halting ovulation.
2025-2026 research sharpens the picture:
- Phenotype differences: IR hits hardest in classic PCOS (phenotype A: obesity + hyperandrogenism), with HOMA-IR scores 50% higher than lean phenotypes.
- Ovarian focus: A February 2026 mouse study pinpointed low kisspeptin in granulosa cells causing local ovarian IR - wrecked mitochondria, high ROS, blocked PI3K/AKT/GLUT4 signaling. Kisspeptin fixed it all.
- Gut & inflammation: Microbiome dysbiosis worsens systemic IR; East Asians show severe IR at lower BMIs.
Prediabetes parallel? PCOS accelerates your progression to type 2 diabetes by 2-4x without intervention. But studies scream reversibility - lifestyle cuts risk 50%+, mirroring DPP trial wins.
Proven Treatments: Targeting IR Head-On
No one-size-fits-all, but insulin sensitizers lead. Guidelines prioritize metabolic fixes before symptom bandaids.
Pharmacology Stars:
- Metformin (500-2000mg/day): Gold standard AMPK activator. Drops HOMA-IR 20-30%, restores cycles in 50%. Caveat: GI upset in 25%.
- Inositols (myo- 2-4g + D-chiro- 50-100mg): "Vitamin-like" messengers rival metformin – 60% ovulation rate boost, no side effects.
- Emerging GLP-1s (semaglutide/liraglutide): Weight loss + direct IR improvement. 2025 trials: superior to metformin for visceral fat and androgens.
New Horizons (2026 Trials):
- Kisspeptin agonists for ovarian IR.
- SGLT2s like empagliflozin for glycosuria-driven sensitivity.
- Berberine: Natural AMPK mimic with anti-androgen punch.
Combine with lifestyle for 80% metabolic response – studies confirm synergy.
Best Lifestyle Changes: High-Leverage Wins for Sensitivity
Lifestyle trumps pills long-term: 5-10% weight loss halves diabetes risk, normalizes insulin in 60%.
Top Evidence-Based Plays:
- Low-GI Diet: Swap refined carbs for fiber bombs (25-30g/day: oats, lentils, berries). Mediterranean style slashes IR 25%; plate rule: ½ veggies, ¼ protein, ¼ whole grains.
- Exercise Combo: 150min moderate aerobic (brisk walk/cycle) + 2x resistance (weights/bodyweight). HIIT 3x/week accelerates GLUT4 to muscles – 30% sensitivity gain.
- Sleep Mastery: 7-9hrs/night. <6hrs spikes cortisol/IR 40%; consistent rhythm stabilizes glucose.
- Stress Tune: 10min daily mindfulness/breathing. Cuts HPA overdrive fueling IR.
Real-world: 2025 meta-analysis – combined interventions beat diet-alone by 2x for ovulation/IR.
| Quick Start | Daily Action | 4-Week Win |
|---|---|---|
| Breakfast | Oats + berries + nuts | Stable AM glucose |
| Move | 30min walk + squats | ↓ HOMA-IR 15% |
| Wind Down | No screens 1hr pre-bed | Better sleep/insulin |
Your Next Move
PCOS-IR isn't destiny – it's data-driven. Start with diet audit + walk; track fasting insulin if possible.
Prediabetes + PCOS? Double motivation for these shifts – halve your risk today.
Next week: Inositols deep-dive – stacks, doses, real results.
Until then,
Prioritize sensitivity. Small systems tweaks compound.
Warmly,
Jackie
✅ PCOS & Prediabetes Action Checklist
Insulin Resistance: Target the Root, Not Just Symptoms. By Jackie Laver
🔎 1. Awareness & Assessment Check
☐ I understand that insulin resistance drives most PCOS cases (even if I’m lean).
☐ I know my latest: HbA1c, fasting glucose, fasting insulin (if available), and lipids.
☐ I understand my PCOS phenotype (classic / lean / mixed).
☐ I’ve discussed metabolic risk (not just cycles/fertility) with my clinician.
Goal: Shift from “hormone problem” thinking → “metabolic driver” action.
🧬 2. Reduce Insulin Load Daily
Plate Audit (Tick what you did today)
☐ My plate was: ½ non-starchy vegetables, ¼ quality protein, ¼ whole-food carbohydrate.
☐ I hit ~25–30g fibre.
☐ I avoided refined carbs at breakfast.
☐ I paired carbs with protein and fat.
Focus: Lower post-meal insulin spikes → calm ovarian androgen drive.
🚶 3. Muscle = Glucose Disposal
☐ I completed 30 minutes of movement today (walk/cycle/swim).
☐ I did resistance work (bodyweight, bands, weights) 2x this week.
☐ I moved within 30 minutes after a carb-heavy meal.
Why: Muscle contraction pulls glucose without needing insulin.
🌙 4. Sleep & Cortisol Reset
☐ I protected 7–9 hours of sleep.
☐ I reduced screens 60 minutes before bed.
☐ I kept a consistent sleep/wake time.
Remember: <6 hours sleep can worsen insulin resistance by ~40%.
🧘 5. Stress & Nervous System Regulation
☐ I did 5–10 minutes of breathing, mindfulness, or grounding.
☐ I avoided “all-or-nothing” thinking about food today.
☐ I protected emotional bandwidth (said no where needed).
Why: Chronic cortisol amplifies insulin resistance.
💊 6. Treatment Discussion (If Applicable)
☐ I’ve discussed metformin (500–2000mg) with my clinician if indicated.
☐ I understand inositol dosing (myo- 2–4g + D-chiro 50–100mg).
☐ I know GLP-1 medications may be considered if weight/metabolic risk is high.
☐ I understand supplements are supportive — not replacements for lifestyle.
📊 7. Track What Matters (4-Week Experiment)
Choose 1–2 metrics only:
☐ Morning fasting glucose
☐ Waist circumference
☐ Cycle regularity
☐ Energy levels
☐ Cravings intensity
Expected Wins in 4 Weeks:
- ↓ HOMA-IR ~10–20% (with combined changes)
- More stable morning glucose
- Improved cycle predictability
- Reduced central fat accumulation
30-Day Insulin Sensitivity Commitment
☐ Walk daily
☐ Lift twice weekly
☐ Eat fibre first
☐ Sleep on schedule
☐ Regulate stress daily
Small metabolic shifts compound.
🔁 Systems Reminder
PCOS + Prediabetes is not a willpower failure. It is a feedback loop.
Break the insulin loop → and hormones follow.
References
Prosperi, S., & colleagues. (2025). Insulin resistance, metabolic syndrome and polycystic ovaries. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1669716
Sun, N., Sun, P., Sun, L., Sun, P., Qi, D., & Ma, H. (2026). Kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway. PLoS ONE, 21(2), Article e0342158. https://doi.org/10.1371/journal.pone.0342158
Kite, C., Lafferty, K., McKenna, J., Clark, C., Corbet, J., & McCarthy, H. (2025). Insulin resistance in polycystic ovary syndrome phenotypes and the vicious cycle model in its etiology. Scientific Reports, 15, Article 26718. https://doi.org/10.1038/s41598-025-26718-2
Li, Y., Zhang, X., & Wang, L. (2026). Precision targeted therapy for PCOS: Emerging drugs, translational challenges, and future opportunities. Frontiers in Endocrinology. https://pmc.ncbi.nlm.nih.gov/articles/PMC12839070/
Wang, J., Liu, H., & Chen, Q. (2026). The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1722649
Teede, H. J., Misso, M. L., & Costello, M. F. (2025). The role of lifestyle interventions in PCOS management: A systematic review. PMC Articles. https://pmc.ncbi.nlm.nih.gov/articles/PMC11767734/
Cioffi, I., Marra, F., & Pasanisi, F. (2025). Impact of lifestyle interventions on reproductive and metabolic outcomes in PCOS: A meta-analysis. PubMed, 39833063. https://pubmed.ncbi.nlm.nih.gov/39833063/
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J., Legro, R., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2025). Polycystic ovary syndrome in 2025—insights and innovations. Fertility and Sterility. https://doi.org/10.1016/j.fertnstert.2025.01.922
Responses